Want to see HK:3759 full AI Analyst Report?
Top Page
Pharmaron Beijing Co., Ltd. Class H
(3759)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$30.00
â–˛(24.28% Upside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak cash generation and cash conversion (minimal free cash flow despite solid earnings) and a high P/E valuation. These are partially offset by still-healthy profitability, a broadly manageable balance sheet (despite rising debt), and strong technical trend support, though momentum is currently overbought.
Positive Factors
End-to-end CRDMO platform
The broad service platform covers multiple stages of drug development, allowing Pharmaron to support customers beyond a single project phase. This integrated model can deepen client relationships, create cross-selling opportunities, and provide recurring demand across discovery, development, and manufacturing activities.
Negative Factors
Weak cash conversion
The gap between reported earnings and internally generated cash is a significant constraint. Very thin free cash flow limits financial flexibility, reduces the funds available for expansion or shareholder returns, and suggests that reinvestment or working-capital needs are absorbing much of the company’s accounting profit.
Read all positive and negative factors
Positive Factors
Negative Factors
End-to-end CRDMO platform
The broad service platform covers multiple stages of drug development, allowing Pharmaron to support customers beyond a single project phase. This integrated model can deepen client relationships, create cross-selling opportunities, and provide recurring demand across discovery, development, and manufacturing activities.
Read all positive factors
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$80.18B
Dividend Yield0.79%
Average Volume (3M)9.94M
Price to Earnings (P/E)42.5
Beta (1Y)1.91
Revenue Growth20.39%
EPS Growth26.48%
CountryHK
Employees25,088
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.96
Shares Outstanding359,977,870
10 Day Avg. Volume10,506,704
30 Day Avg. Volume9,939,233
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$37.94Price Target Upside57.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.26
Revenue Forecast (FY)HK$19.42B
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laborat...
How the Company Makes Money
Pharmaron makes money primarily by providing fee-for-service outsourced R&D and manufacturing services to pharmaceutical, biotech, and other life-sciences customers under contract. Key revenue streams typically include: (1) Drug discovery and prec...
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
70
Positive
Cash Flow
42
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.08B | 14.10B | 12.28B | 11.54B | 10.27B | 7.44B |
| Gross Profit | 5.06B | 4.91B | 4.20B | 4.12B | 3.77B | 2.68B |
| EBITDA | 2.57B | 3.29B | 3.38B | 2.95B | 2.53B | 2.49B |
| Net Income | 1.71B | 1.66B | 1.79B | 1.60B | 1.37B | 1.66B |
Balance Sheet | ||||||
| Total Assets | 29.13B | 27.09B | 23.93B | 26.48B | 20.49B | 18.39B |
| Cash, Cash Equivalents and Short-Term Investments | 2.45B | 1.73B | 2.81B | 6.72B | 2.24B | 5.10B |
| Total Debt | 6.95B | 3.42B | 5.54B | 9.36B | 6.12B | 5.29B |
| Total Liabilities | 11.63B | 11.36B | 9.70B | 13.24B | 9.65B | 8.09B |
| Stockholders Equity | 16.35B | 15.06B | 13.62B | 12.56B | 10.55B | 10.13B |
Cash Flow | ||||||
| Free Cash Flow | 50.01M | 551.97M | 536.02M | -111.78M | -807.04M | -34.78M |
| Operating Cash Flow | 2.95B | 3.22B | 2.58B | 2.75B | 2.14B | 2.06B |
| Investing Cash Flow | -4.02B | -4.37B | -2.02B | -2.25B | -2.21B | -5.26B |
| Financing Cash Flow | 1.39B | 377.00M | -4.80B | 3.92B | -1.42B | 3.66B |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Neutral
24.14
Price Trends
25.52
Positive
21.85
Positive
21.24
Positive
Market Momentum
1.01
Positive
52.68
Neutral
27.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3759, the sentiment is Neutral. The current price of 24.14 is below the 20-day moving average (MA) of 30.21, below the 50-day MA of 25.52, and above the 200-day MA of 21.24, indicating a neutral trend. The MACD of 1.01 indicates Positive momentum. The RSI at 52.68 is Neutral, neither overbought nor oversold. The STOCH value of 27.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3759.
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$204.24B | 34.73 | 10.51% | ― | 21.93% | 21.94% | |
68 Neutral | HK$66.90B | 56.21 | 5.86% | 1.12% | 16.62% | >-0.01% | |
62 Neutral | HK$68.87B | -13.44 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$2.78B | 13.89 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$80.18B | 42.46 | 10.96% | 0.79% | 20.39% | 26.48% | |
58 Neutral | HK$2.64B | 31.76 | 3.02% | ― | 10.32% | 178.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3759
Pharmaron Beijing Co., Ltd. Class H
29.00
5.11
21.39%
HK:1548
Genscript Biotech
31.46
13.38
74.00%
HK:2269
Wuxi Biologics (Cayman)
49.18
10.20
26.17%
HK:1521
Frontage Holdings Corp.
1.30
-0.04
-2.63%
HK:1873
Viva Biotech Holdings
1.34
-1.46
-52.32%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
133.80
36.45
37.44%
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Completes US$330 Million Convertible Bond Issue to Fund Expansion
Sep 2, 2026
Pharmaron Beijing Co., Ltd. has completed the issuance of RMB2.18 billion in USD-settled zero coupon convertible bonds due 2027 under its general mandate, with the closing occurring on September 2, 2026. The bonds are convertible into H shares at ...
Pharmaron Beijing to Raise US$330 Million via Premium-Priced Convertible Bonds
Aug 26, 2026
Pharmaron Beijing plans to issue RMB2,180 million worth of USD-settled zero coupon convertible bonds due 2027 under its general mandate, following a book-building process that has set key terms. The bonds will be subscribed by a manager who may pr...
Pharmaron Beijing Calls 2026 H Share Class Meeting to Seek Repurchase Mandate
Aug 25, 2026
Pharmaron Beijing Co., Ltd. has called its first H share class meeting of 2026 for September 10 in Beijing, immediately following its extraordinary general meeting and A share class meeting. The session will ask H shareholders to consider and appr...
Pharmaron Beijing Calls 2026 EGM to Approve Incentive, Buyback and Offshore Debt Plans
Aug 25, 2026
Pharmaron Beijing Co., Ltd. has convened its first extraordinary general meeting of 2026 for September 10 in Beijing, inviting H shareholders of record as of September 7 to attend and vote. The meeting notice details procedures for share registrat...
Pharmaron Sets H Share Register Closure for 2026 Extraordinary Meetings
Aug 21, 2026
Pharmaron Beijing Co., Ltd. has announced administrative arrangements for its H shareholders ahead of the First Extraordinary General Meeting of 2026 and the First H Share Class Meeting of 2026, both scheduled for the afternoon of 10 September 202...
Pharmaron Beijing Posts Solid H1 2026 Growth But Holds Interim Dividend
Aug 20, 2026
Pharmaron Beijing Co., Ltd. reported interim results for the six months ended June 30, 2026, showing revenue of RMB7.60 billion, up 17.9% year-on-year, and profit attributable to owners of the parent rising 7.0% to RMB750.2 million. Non-IFRS adjus...
Pharmaron Reshapes Segment Reporting to Highlight Integrated Multi‑Modality R&D Platform
Aug 20, 2026
Pharmaron Beijing Co., Ltd. has reorganized its business and adjusted its segment reporting to better reflect its integrated pharmaceutical RD services platform. The company is consolidating its offerings into three core segments—laboratory ...
Pharmaron Schedules Board Meeting to Approve 2026 Interim Results
Aug 6, 2026
Pharmaron Beijing Co., Ltd. has scheduled a board meeting for August 20, 2026, to review and approve the interim results for the six months ended June 30, 2026, and to consider their publication. The announcement signals the company’s prepar...
Pharmaron Unveils 2026 H Share Incentive Plan and Governance Overhaul
Jul 24, 2026
Pharmaron Beijing Co., Ltd. plans to adopt a new 2026 H Share award and trust scheme, authorizing up to 28 million H shares sourced from repurchased treasury stock and potential new issuances. The 10-year scheme is designed to strengthen its equit...
Pharmaron Forecasts Double-Digit Revenue Growth for Interim 2026 Results
Jul 13, 2026
Pharmaron Beijing Co., Ltd. expects a solid improvement in its interim 2026 financial results, projecting revenue between RMB 7.47 billion and RMB 7.66 billion, a year-on-year increase of 16% to 19%. Net profit attributable to shareholders is esti...
Pharmaron Restructures H Share Awards Amid FX Policy Changes
Jul 2, 2026
Pharmaron Beijing Co., Ltd. has restructured its employee H share incentive arrangements to comply with changes in foreign exchange administrative policies affecting its share award schemes. The move reflects the company’s effort to maintain...
Pharmaron Reshapes Board Committees to Bolster Governance and Strategy
Jun 15, 2026
Pharmaron Beijing Co., Ltd. has announced the composition of its fourth session board of directors, naming executive, non-executive, independent and employee representative directors, with Dr. Lou Boliang serving as chairman. The company has also ...
Pharmaron Shareholders Approve 2025 AGM Resolutions, Dividend Plan and Governance Changes
Jun 12, 2026
Pharmaron Beijing Co., Ltd. reported the results of its 2025 annual general meeting in Beijing, confirming that the meeting was validly convened under PRC law and its Articles of Association, with about 48.7% of voting shares represented. All dire...
Pharmaron Beijing Sets New Board Line-Up and Prepares Committee Appointments
Jun 12, 2026
Pharmaron Beijing Co., Ltd. has outlined the composition of its new board of directors, naming executive, non-executive, independent non-executive and employee representative directors to oversee the company. The move formalizes its governance fra...
Pharmaron Sets Updated Final Cash Dividend and Clarifies Tax Treatment for 2025
Jun 12, 2026
Pharmaron Beijing Co., Ltd. has announced an updated final cash dividend for the financial year ended 31 December 2025, setting the distribution at RMB 2 per 10 shares, with Hong Kong shareholders receiving HKD 2.299274 per 10 shares based on an e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.